One serious candidate to consider along those lines is CRISPR Therapeutics (CRSP 0.63%). This biotech company is somewhat risky, but it could generate strong returns in the long run. While people with this disease are normally unable to produce their own insulin, CRISPR Therapeutics' goal with CTX211 is to restore that ability. CRISPR Therapeutics' gene-editing platform looks promising because of its ability to develop transformative therapies in areas with high unmet needs. It has done so before: The biotech company has earned approval for Casgevy, a medicine that treats two rare blood disorders.